| ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About | |
A Randomized Study to Evaluate FK962 in Subjects with Mild to Moderate Alzheimer's Disease
This study is currently recruiting patients.
| Sponsored by: | Fujisawa Healthcare, Inc.
Fujisawa Pharmaceutical
|
|---|---|
| Information provided by: | Fujisawa Healthcare, Inc. |
Purpose
The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Alzheimer's Disease |
Drug: FK962 |
Phase II |
MedlinePlus related topics: Alzheimer's Caregivers; Alzheimer's Disease
Genetics Home Reference related topics: Alzheimer disease
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of FK962 in Subjects with Mild to Moderate Alzheimer's Disease
Expected Total Enrollment: 510
Study start: July 2004
Eligibility
Ages Eligible for Study: 50 Years - 90 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
Exclusion Criteria:
Location
and Contact
Information
More Information
 | ||||||||||||||
| U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
| National Institutes of Health, Department of Health & Human Services | ||||||||||||||
| Copyright, Privacy, Accessibility, Freedom of Information Act | ||||||||||||||